MEN2A
MCID: MLT024
MIFTS: 64

Multiple Endocrine Neoplasia Iia (MEN2A) malady

Categories: Genetic diseases, Rare diseases, Gastrointestinal diseases, Endocrine diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Multiple Endocrine Neoplasia Iia

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 37MedGen, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Multiple Endocrine Neoplasia Iia:

Name: Multiple Endocrine Neoplasia Iia 52 12
Multiple Endocrine Neoplasia Type 2a 11 48 24 54 27 39 13 68
Multiple Endocrine Neoplasia Type 2 23 48 24 54 27 68
Sipple Syndrome 11 48 24 54
Men2a 11 24 54 70
Men2 48 24 54 70
Men 2a 48 24 50
Men2 Syndrome 23 24
 
Ptc Syndrome 48 54
Men 2 23 24
Pheochromocytoma and Amyloid Producing Medullary Thyroid Carcinoma 48
Multiple Endocrine Neoplasia, Type Iia 52
Multiple Endocrine Neoplasia Ii 11
Multiple Neoplasia Type 2 70
Multiple Neoplasia 2a 70
Men-2a Syndrome 48

Characteristics:

Orphanet epidemiological data:

54
multiple endocrine neoplasia type 2:
Inheritance: Autosomal dominant; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy
multiple endocrine neoplasia type 2a:
Inheritance: Autosomal dominant; Age of onset: Childhood; Age of death: normal life expectancy

HPO:

64
multiple endocrine neoplasia iia:
Inheritance: autosomal dominant inheritance

GeneReviews:

23
Penetrance: the penetrance for mtc, pheochromocytoma, and parathyroid disease varies by men 2 subtype (see table 2)...


Classifications:



External Ids:

OMIM52 171400
Disease Ontology11 DOID:0050430
ICD1030 E31.22
ICD9CM32 258.02
MeSH39 D018813
NCIt45 C3226
SNOMED-CT62 61808009
ICD10 via Orphanet31 D44.8
UMLS via Orphanet69 C0025268
MESH via Orphanet40 D018813
MedGen37 C0025268

Summaries for Multiple Endocrine Neoplasia Iia

About this section
NIH Rare Diseases:48 Multiple endocrine neoplasia type 2 (men2) is an inherited disorder in which one or more of the endocrine glands are overactive or form a tumor. endocrine glands most commonly involved include: adrenal (about half the time) parathyroid (20% of the time) thyroid (almost all of the time) men2 is caused by a defect in the ret gene. this defect causes many tumors to appear in the same person, but not necessarily at the same time. the adrenal tumor is called a pheochromocytoma, and the thyroid tumor is a medullary carcinoma of the thyroid. the condition is usually inherited in an autosomal dominant pattern. men2 is divided into three subtypes: type 2a, type 2b, and familial medullary thyroid carcinoma (fmtc). these subtypes differ in their characteristic signs and symptoms and risk of specific tumors. the features of this disorder are relatively consistent within any one family. last updated: 9/2/2015

MalaCards based summary: Multiple Endocrine Neoplasia Iia, also known as multiple endocrine neoplasia type 2a, is related to pheochromocytoma and adrenal carcinoma, and has symptoms including Array, Array and Array. An important gene associated with Multiple Endocrine Neoplasia Iia is RET (Ret Proto-Oncogene), and among its related pathways are NCAM1 interactions and Transcription_Role of VDR in regulation of genes involved in osteoporosis. Affiliated tissues include thyroid, tongue and colon, and related mouse phenotypes are neoplasm and digestive/alimentary.

UniProtKB/Swiss-Prot:70 Multiple neoplasia 2A: The most frequent form of medullary thyroid cancer (MTC). It is an inherited cancer syndrome characterized by MTC, phaeochromocytoma and/or hyperparathyroidism.

OMIM:52 Multiple endocrine neoplasia type IIA is an autosomal dominant syndrome of multiple endocrine neoplasms, including... (171400) more...

Disease Ontology:11 An autosomal dominant disease characterized by medullary carcinoma of the thyroid, pheochromocytoma, hyperparathyroidism, and occasionally cutaneous lichen amyloidosis.

GeneReviews for NBK1257

Related Diseases for Multiple Endocrine Neoplasia Iia

About this section

Diseases in the Multiple Endocrine Neoplasia family:

multiple endocrine neoplasia iia Multiple Endocrine Neoplasia Iib
Multiple Endocrine Neoplasia 1 Multiple Endocrine Neoplasia, Type Iv

Diseases related to Multiple Endocrine Neoplasia Iia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 81)
idRelated DiseaseScoreTop Affiliating Genes
1pheochromocytoma28.8CALCA, GDNF, MEN1, NF1, RET, SDHB
2adrenal carcinoma11.1
3medullary thyroid carcinoma, familial10.8
4multiple endocrine neoplasia 110.8
5gastrinoma10.3CALCA, RET
6meigel disease10.3GDNF, RET
7pemphigus foliaceus10.3CALCA, MEN1
8paranasal sinus cancer, adult10.3CALCA, MEN1
9hypoparathyroidism-intellectual disability-dysmorphism syndrome10.2GDNF, RET
10early-onset parkinson disease10.2MEN1, RET
11restless legs syndrome 710.2CDC73, MEN1
12multiple endocrine neoplasia10.2
13gemistocytic astrocytoma10.2CALCA, MEN1
14connective tissue cancer10.2CALCA, GDNF, RET
15stickler syndrome10.2CALCA, PTH
16muscular dystrophy-dystroglycanopathy , type a, 1010.2CALCA, MEN1, RET
17macular holes10.2MEN1, PTH
18mitochondrial complex ii deficiency10.1MEN1, SDHD
19cardioauditory syndrome of sanchez cascos10.1CALCA, MEN1
20neuropathy, congenital, with arthrogryposis multiplex10.1SDHB, SDHD
21hyperparathyroidism, familial primary10.1CDC73, MEN1, RET
22skin pilomatrix carcinoma10.1GDNF, GFRA1, RET
23hypophosphatasia, adult10.1CALCA, PTH
24paraganglioma and gastric stromal sarcoma10.1SDHB, SDHD
25mesenchymal cell neoplasm10.1CALCA, PTH
26gastroduodenal crohn's disease10.1GDNF, GFRA1
27waardenburg syndrome, type 4b10.1CALCA, PTH
28glioma susceptibility 210.1SDHB, SDHD
29keloids10.1CALCA, MEN1
30tooth agenesis, selective, 510.1GDNF, GFRA1, RET
31amaurosis congenita, cone-rod type, with congenital hypertrichosis10.1SDHB, SDHD
32serous surface papilloma10.1SDHB, SDHD
33glomangioma10.1SDHB, SDHD
34familial chronic myelocytic leukemia-like syndrome10.1CDC73, PTH
35strabismus10.1MEN1, PTH
36brain ependymoma10.1CALCA, NF1
37adult ependymoblastoma10.1CALCA, MEN1, PTH
38catastrophic antiphospholipid syndrome10.1RET, SDHB, SDHD
39acrocapitofemoral dysplasia10.0RET, SDHB, SDHD
40bone ameloblastoma10.0RET, SDHB, SDHD
41intravenous leiomyomatosis10.0RET, SDHB, SDHD
42endocervical adenocarcinoma10.0RET, SDHB, SDHD
43cardiac arrest10.0RET, SDHB, SDHD
44glycogen storage disease ic10.0SDHB, SDHD
45childhood vagina botryoid rhabdomyosarcoma10.0CALCA, NF1
46endocrine gland cancer10.0CALCA, MEN1, RET, SDHD
47pes anserinus tendinitis or bursitis10.0CALCA, PTH
48immune system organ benign neoplasm10.0CDC73, MEN1, PTH
49acrorenal syndrome10.0CALCA, PTH
50t-cell large granular lymphocyte leukemia10.0MEN1, NF1, RET

Graphical network of the top 20 diseases related to Multiple Endocrine Neoplasia Iia:



Diseases related to multiple endocrine neoplasia iia

Symptoms & Phenotypes for Multiple Endocrine Neoplasia Iia

About this section

Symptoms by clinical synopsis from OMIM:

171400

Clinical features from OMIM:

171400

Human phenotypes related to Multiple Endocrine Neoplasia Iia:

 54 64 (show all 67)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 tall stature64 54 Occasional (29-5%) HP:0000098
2 abnormality of the tongue64 54 Frequent (79-30%) HP:0000157
3 cleft palate64 54 Occasional (29-5%) HP:0000175
4 thick lower lip vermilion64 54 Frequent (79-30%) HP:0000179
5 abnormality of the eyelid64 54 Frequent (79-30%) HP:0000492
6 depression64 54 Frequent (79-30%) HP:0000716
7 anxiety64 54 Frequent (79-30%) HP:0000739
8 pectus excavatum64 54 Occasional (29-5%) HP:0000767
9 nephrolithiasis64 54 Occasional (29-5%) HP:0000787
10 diabetes mellitus64 54 Frequent (79-30%) HP:0000819
11 hypertension64 54 Frequent (79-30%) HP:0000822
12 hyperparathyroidism64 54 Occasional (29-5%) HP:0000843
13 dry skin64 54 Frequent (79-30%) HP:0000958
14 pallor64 54 Occasional (29-5%) HP:0000980
15 skin rash64 54 Occasional (29-5%) HP:0000988
16 pruritus64 54 Occasional (29-5%) HP:0000989
17 multiple lipomas64 54 Occasional (29-5%) HP:0001012
18 corneal dystrophy64 54 Occasional (29-5%) HP:0001131
19 arachnodactyly64 54 Occasional (29-5%) HP:0001166
20 muscular hypotonia64 54 Occasional (29-5%) HP:0001252
21 muscle weakness64 54 Occasional (29-5%) HP:0001324
22 tremor64 54 Occasional (29-5%) HP:0001337
23 pes cavus64 54 Occasional (29-5%) HP:0001761
24 weight loss64 54 Occasional (29-5%) HP:0001824
25 dehydration64 54 Occasional (29-5%) HP:0001944
26 diarrhea64 54 Very frequent (99-80%) HP:0002014
27 nausea and vomiting64 54 Occasional (29-5%) HP:0002017
28 constipation64 54 Frequent (79-30%) HP:0002019
29 abdominal pain64 54 Frequent (79-30%) HP:0002027
30 anorexia64 54 Occasional (29-5%) HP:0002039
31 aganglionic megacolon64 54 Occasional (29-5%) HP:0002251
32 hypotension64 54 Frequent (79-30%) HP:0002615
33 scoliosis64 54 Occasional (29-5%) HP:0002650
34 bone pain64 54 Occasional (29-5%) HP:0002653
35 pheochromocytoma64 54 Frequent (79-30%) HP:0002666
36 lymphadenopathy64 54 Frequent (79-30%) HP:0002716
37 kyphosis64 54 Occasional (29-5%) HP:0002808
38 medullary thyroid carcinoma64 54 Very frequent (99-80%) HP:0002865
39 ganglioneuroma64 54 Occasional (29-5%) HP:0003005
40 hypercalcemia64 54 Occasional (29-5%) HP:0003072
41 slender long bone64 54 Occasional (29-5%) HP:0003100
42 myopathy64 54 Frequent (79-30%) HP:0003198
43 hyperlordosis64 54 Occasional (29-5%) HP:0003307
44 paresthesia64 54 Occasional (29-5%) HP:0003401
45 abnormality of temperature regulation64 54 Occasional (29-5%) HP:0004370
46 reduced consciousness/confusion64 54 Occasional (29-5%) HP:0004372
47 intestinal obstruction64 54 Occasional (29-5%) HP:0005214
48 joint hyperflexibility64 54 Occasional (29-5%) HP:0005692
49 patellar aplasia64 54 Occasional (29-5%) HP:0006443
50 irregular hyperpigmentation64 54 Frequent (79-30%) HP:0007400
51 multiple cafe-au-lait spots64 54 Occasional (29-5%) HP:0007565
52 adrenal hyperplasia64 54 Frequent (79-30%) HP:0008221
53 peripheral neuropathy54 Occasional (29-5%)
54 edema of the lower limbs64 54 Occasional (29-5%) HP:0010741
55 arrhythmia64 54 Occasional (29-5%) HP:0011675
56 abnormality of oral mucosa64 54 Frequent (79-30%) HP:0011830
57 fatigue64 54 Frequent (79-30%) HP:0012378
58 increased inflammatory response54 Occasional (29-5%)
59 neoplasm of the adrenal gland64 54 Frequent (79-30%) HP:0100631
60 hypertensive crisis64 54 Frequent (79-30%) HP:0100735
61 benign neoplasm of the central nervous system64 54 Occasional (29-5%) HP:0100835
62 intestinal polyposis64 54 Occasional (29-5%) HP:0200008
63 abnormality of the integument64 HP:0001574
64 parathyroid adenoma64 HP:0002897
65 increased circulating cortisol level64 HP:0003118
66 elevated calcitonin64 HP:0003528
67 elevated urinary epinephrine64 HP:0003639

MGI Mouse Phenotypes related to Multiple Endocrine Neoplasia Iia according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.9MEN1, NF1, RET, SDHB, SDHD
2MP:00053818.8CDC73, GDNF, GFRA1, MEN1, NF1, RET
3MP:00053698.7CDC73, GDNF, GFRA1, MEN1, NF1, RET
4MP:00053808.7CDC73, GFRA1, MEN1, NF1, RET, SDHD
5MP:00053678.2CDC73, GDNF, GFRA1, NF1, RET
6MP:00053878.1CDC73, GDNF, GFRA1, MEN1, NF1, PTH
7MP:00036317.7CDC73, GDNF, GFRA1, MEN1, NF1, RBP3
8MP:00053857.5CDC73, GDNF, MEN1, NF1, PTH, RET
9MP:00053797.5CDC73, GDNF, MEN1, NF1, PTH, RET
10MP:00107687.1CDC73, GDNF, GFRA1, MEN1, NF1, PTH

Drugs & Therapeutics for Multiple Endocrine Neoplasia Iia

About this section

Drugs for Multiple Endocrine Neoplasia Iia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 380)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sunitinibapproved, investigationalPhase 4, Phase 2510341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
2
MetforminapprovedPhase 4, Phase 3, Phase 21803657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
3
CabergolineapprovedPhase 4, Phase 34681409-90-754746
Synonyms:
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
81409-90-7
85329-89-1 (diphosphate)
AC-14150
AC1L1HO0
AC1Q5OQ0
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
CG-101
CHEBI:3286
 
CHEMBL1201087
CID54746
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergolinum
Cabergolinum [Latin]
D00987
DB00248
Dostinex
Dostinex (TN)
FCE-21336
FT-0081285
Galastop
HMS2090A09
LS-64370
MolPort-003-845-557
Sogilen
UNII-LL60K9J05T
cabergoline
4
Diazepamapproved, illicit, vet_approvedPhase 4, Phase 1126439-14-53016
Synonyms:
1-Methyl-5-phenyl-7-chloro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
11100-37-1
439-14-5
5-24-04-00300 (Beilstein Handbook Reference)
53320-84-6
7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
7-Chloro-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepine
7-Chloro-1-methyl-5-3H-1,4-benzodiazepin-2(1H)-one
7-Chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
7-Chloro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
7-Chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one
7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
A3662/0155188
AC-10561
AC1L1EZE
AKOS003367969
Alboral
Aliseum
Alupram
Amiprol
An-Ding
Ansilive
Ansiolin
Ansiolisina
Antenex
Anxicalm
Anxionil
Apaurin
Apo-Diazepam
Apo-diazepam
Apozepam
Armonil
Arzepam
Assival
Atensine
Atilen
Azedipamin
BIDD:GT0105
BIDD:PXR0158
BRD-K16508793-001-01-8
BRN 0754371
BSPBio_003279
Baogin
Bensedin
Benzopin
Best [Pharaceutical]
Betapam
Bialzepam
Britazepam
C06948
CB 4261
CCRIS 6009
CHEBI:49575
CHEMBL12
CID3016
CPD000058398
Calmaven
Calmocitene
Calmociteno
Calmod
Calmpose
Caudel
Centrazepam
Cercine
Ceregulart
Chuansuan
Condition
D-Pam
D00293
D003975
D0899_SIGMA
D9900_FLUKA
D9900_SIGMA
DAP
DB00829
DB07699
DEA No. 2765
DZP
Desconet
Desloneg
Diacepan
Diaceplex
Dialag
Dialar
Diapam
Diapax
Diapine
Diaquel
Diastat
Diastat (TN)
Diastat Acudial
Diatran
Diazapam
Diazem
Diazemuls
Diazemulus
Diazepam
Diazepam (JP15/USP/INN)
Diazepam Dak
Diazepam Desitin
Diazepam Elmu
Diazepam Fabra
Diazepam Intensol
Diazepam Nordic
Diazepam Rectubes
Diazepam Stada
Diazepam [USAN:INN:BAN:JAN]
Diazepam solution
Diazepam-Eurogenerics
Diazepam-Lipuro
Diazepam-ratiopharm
Diazepamu
Diazepamu [Polish]
Diazepamum
Diazepamum [INN-Latin]
Diazepan
Diazepan leo
Diazepin
Diazetard
Dienpax
Dipam
Dipaz
Dipezona
Disopam
DivK1c_000967
Dizac
Domalium
Doval
Drenian
Ducene
Duksen
Dupin
Duxen
E-Pam
EINECS 207-122-5
Elcion CR
Eridan
Euphorin P
Eurosan
Evacalm
Faustal
Faustan
Faustan,
Freudal
Frustan
Gewacalm
Gihitan
Gradual
Gubex
HMS2051N04
HMS503A15
HSDB 3057
I06-0194
IDI1_000967
Iazepam
 
Jinpanfan
KBio1_000967
KBio3_002780
KBioGR_001012
Kabivitrum
Kiatrium
Kratium
Kratium 2
LA 111
LA III
LA-111
LS-122
La-Iii
Lamra
Lembrol
Levium
Liberetas
Lizan
Lovium
MLS000759402
Mandro
Mandro-Zep
Mandrozep
Medipam
Mentalium
Metamidol
Methyl diazepinone
Methyldiazepinone
Methyldiazepinone (pharmaceutical)
Methyldiazepinone, pharmaceutical
Metil Gobanal
MolPort-001-729-114
Morosan
NCGC00178168-01
NINDS_000967
NSC 169897
NSC-77518
NSC169897
NSC77518
Nellium
Nerozen
Nervium
Neurolytril
Nivalen
Nixtensyn
Noan
Notense
Novazam
Novo-Dipam
Novodipam
Oprea1_126223
Ortopsique
Paceum
Pacitran
Paralium
Paranten
Parzam
Paxate
Paxel
Paxum
Placidox 10
Placidox 2
Placidox 5
Plidan
Pms-Diazepam
Pomin
Pro-Pam
ProPAM
Prozepam
Psychopax
Q-Pam
Q-Pam Relanium
Q-pam
Quetinil
Quiatril
Quievita
Radizepam
Relaminal
Relanium
Reliver
Renborin
Ro 5-2805
Ro 5-2807
Ruhsitus
S.A. R.L
S.a. r.l.
SAM001246536
SMR000058398
STK735517
Saromet
Sedapam
Sedipam
Seduksen
Seduxen
Serenack
Serenamin
Serenzin
Servizepam
Setonil
Sibazon
Sibazone
Sico Relax
Simasedan
Sipam
Solis
Sonacon
Spectrum3_001780
Spectrum4_000576
Spectrum5_001890
Stesolid
Stesolin
T-quil
Tensium
Tensopam
Tranimul
Trankinon
Tranqdyn
Tranquase
Tranquirit
Tranquo-Puren
Tranquo-Tablinen
Tranquo-puren
Tranquo-tablinen
Trazepam
UNII-Q3JTX2Q7TU
Umbrium
Unisedil
Usempax Ap
Usempax ap
Valaxona
Valeo
Valiquid
Valitran
Valium
Valium (TN)
Valium R
Valrelease
Valuzepam
Vanconin
Vatran
Vazen
Vazepam
Velium
Vival
Vivol
WLN: T67 GNV JN IHJ CG G1 KR
WY-3467
Winii
Wy 3467
ZINC00006427
Zepaxid
Zetran
Zipan
diazepam
e-Pam
nchembio.307-comp2
nchembio747-comp27
neurolytr il
5
ZincapprovedPhase 4, Phase 322967440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
6
Insulin LisproapprovedPhase 4240133107-64-9
Synonyms:
Insulin lispro (genetical recombination)
Insulin lispro (rDNA origin)
Insulin lispro protamine
 
Insulin lispro protamine recombinant
Insulin lispro recombinant
Insulin,lispro,human/rDNA
Insulin,lispro,protamine/rDNA
7
DopamineapprovedPhase 4, Phase 3, Phase 2383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
8
Dexamethasoneapproved, investigational, vet_approvedPhase 4, Phase 1, Phase 2217150-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
9
SimvastatinapprovedPhase 451979902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
10
SomatostatinapprovedPhase 4, Phase 3, Phase 223738916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
11
Insulin GlargineapprovedPhase 4528160337-95-1
Synonyms:
 
Insulin Glargine (rDNA origin)
Insulin glargine recombinant
12
LiraglutideapprovedPhase 4, Phase 3329204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
 
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
13
IronapprovedPhase 4, Phase 311657439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
14
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
15
Vitamin Capproved, nutraceuticalPhase 453150-81-75785, 54670067
Synonyms:
(+)-Sodium L-ascorbate
(+)-ascorbate
(+)-ascorbic acid
(2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one
(2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one
(5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one
129940-97-2
134-03-2 (monosodium salt)
14536-17-5
154170-90-8
2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one
255564_SIAL
259133-78-3
3-Keto-L-gulofuranolactone
3-Oxo-L-gulofuranolactone
3-Oxo-L-gulofuranolactone (enol form)
30208-61-8
33034_RIEDEL
33034_SIAL
47863_SUPELCO
47A605F0-4187-47A8-B0CE-F9E7DA1B0076
50-81-7
50976-75-5
56172-55-5
56533-05-2
57304-74-2
57606-40-3
623158-95-2
6730-29-6
882690-91-7
884381-69-5
885512-24-3
88845-26-5
89924-69-6
95209_FLUKA
95209_SIGMA
95210_FLUKA
95210_SIAL
95212_FLUKA
A0278_SIGMA
A0537
A2174_SIGMA
A2218_SIGMA
A2343_SIGMA
A4403_SIGMA
A4544_SIGMA
A5960_SIGMA
A7506_SIGMA
A92902_ALDRICH
A92902_SIAL
AB00376923
AB1002440
AC1L1L4T
AC1Q77S6
AR-1J3435
Acid Ascorbic
Acide ascorbique
Acide ascorbique [INN-French]
Acido ascorbico
Acido ascorbico [INN-Spanish]
Acidum ascorbicum
Acidum ascorbicum [INN-Latin]
Acidum ascorbinicum
Adenex
Allercorb
Ambap36431-82-0
Antiscorbic vitamin
Antiscorbutic factor
Antiscorbutic vitamin
Arco-cee
Ascoltin
Ascoltin (TN)
Ascor-B.I.D.
Ascorb
Ascorbajen
Ascorbate
Ascorbic Acid
Ascorbic Acid, Monosodium Salt
Ascorbic acid
Ascorbic acid (JP15/USP/INN)
Ascorbic acid [BAN:INN:JAN]
Ascorbic acid [INN:BAN:JAN]
Ascorbicab
Ascorbicap
Ascorbicap (TN)
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorbyl radical
Ascorin
Ascorteal
Ascorvit
BPBio1_000363
BSPBio_000329
C-Level
C-Long
C-Quin
C-Span
C-Vimin
C00072
C6H8O6
CCRIS 57
CE-VI-Sol
CHEBI:29073
CHEMBL196
CID5785
Cantan
Cantaxin
Caswell No. 061B
Catavin C
Ce lent
Ce-Mi-Lin
Ce-mi-lin
Ce-vi-sol
Cebicure
Cebid
Cebion
Cebione
Cecon
Cee-Caps TD
Cee-Vite
Cee-caps TD
Cee-vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-Caps TC
Cetane-Caps TD
Cetane-caps TC
Cetane-caps TD
Cetebe
Cetemican
Cevalin
 
Cevatine
Cevex
Cevi-Bid
Cevi-bid
Cevimin
Cevital
Cevitamate
Cevitamic acid
Cevitamin
Cevitan
Cevitex
Cewin
Chewcee
Ciamin
Cipca
Citriscorb
Citrovit
Colascor
Concemin
Cortalex
D00018
DB00126
Davitamon C
Dora-C-500
Duoscorb
EINECS 200-066-2
FEMA No. 2109
Ferancee
Ferrous ascorbate
HSDB 818
HiCee
Hicee
Hybrin
IDO-C
Ido-C
Iron(II) ascorbate
Iron-ascorbic acid complexes
Juvamine
Kangbingfeng
Kyselina askorbova
Kyselina askorbova [Czech]
L(+)-Ascorbate
L(+)-Ascorbic acid
L-(+)-Ascorbate
L-(+)-Ascorbic Acid
L-(+)-Ascorbic acid
L-(+)-ascorbic acid
L-3-Ketothreohexuronic acid lactone
L-3-ketothreohexuronic acid
L-Ascorbate
L-Ascorbic Acid
L-Ascorbic acid
L-Ascorbic acid, free radical form
L-Lyxoascorbate
L-Lyxoascorbic acid
L-Threo-ascorbic acid
L-Threoascorbic acid
L-Xyloascorbate
L-Xyloascorbic acid
L-ascorbate
L-threo-Hex-2-enonic acid, gamma-lactone
L-threo-ascorbic acid
L-threo-hex-2-enono-1,4-lactone
LS-145
Laroscorbine
Lemascorb
Liqui-Cee
Liqui-cee
MLS002153776
Magnesium Ascorbicum
Magnorbin
Meri-C
Meri-c
MolPort-001-792-501
Monodehydroascorbic acid
NCGC00091517-01
NCGC00091517-02
NCGC00164357-01
NCI-C54808
NSC 33832
Natrascorb
Natrascorb injectable
Oral Vitamin C
Planavit C
Prestwick3_000325
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
Roscorbic
Rovimix C
SMR001233160
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
Sodascorbate
Sodium Ascorbate (Ascorbic Acid)
Stuartinic
Suncoat VC 40
Sunkist
Testascorbic
Tolfrinic
UNII-PQ6CK8PD0R
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100M
Vitace
Vitacee
Vitacimin
Vitacin
Vitamin C
Vitamin- C
Vitamin-?C
Vitamisin
Vitascorbol
W210901_ALDRICH
Xitix
acide ascorbique
acidum ascorbicum
acidum ascorbinicum
antiscorbic vita min
ascor-b.i.d
ascorbate
ascorbic acid
bmse000182
cee-caps td
cevibid
component of Cortalex
component of E and C-Level
component of Endoglobin Forte
component of Ferancee
gamma-Lactone L-threo-Hex-2-enonate
gamma-Lactone L-threo-Hex-2-enonic acid
l-ascorbic acid
l-threo-hex-1-eofuranos-3-ulose
nchembio.174-comp5
nchembio.89-comp1
nchembio.92-comp2
nchembio821-comp9
roscorbi c
vitamin C
ácido ascórbico
16Angiogenesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14257
17Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113180
18HormonesPhase 4, Phase 3, Phase 2, Phase 114415
19Vitamin B ComplexPhase 4, Phase 3, Phase 2, Phase 14337
20MicronutrientsPhase 4, Phase 3, Phase 2, Phase 16001
21Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 2, Phase 14185
22Lipid Regulating AgentsPhase 42766
23AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 112054
24VitaminsPhase 4, Phase 3, Phase 2, Phase 15282
25Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113168
26insulinPhase 4, Phase 3, Phase 1, Phase 24646
27Hypolipidemic AgentsPhase 42785
28Trace ElementsPhase 4, Phase 3, Phase 2, Phase 16001
29Imatinib MesylatePhase 4600123596
30Insulin, Globin ZincPhase 4, Phase 3, Phase 1, Phase 24645
31Hypoglycemic AgentsPhase 4, Phase 3, Phase 25896
32Sitagliptin PhosphatePhase 4, Phase 3423
33
protease inhibitorsPhase 4, Phase 3, Phase 1, Phase 25471
Synonyms:
 
protease inhibitors
34IncretinsPhase 4, Phase 31579
35Dipeptidyl-Peptidase IV InhibitorsPhase 4, Phase 3862
36HIV Protease InhibitorsPhase 4, Phase 3, Phase 1, Phase 25470
37Dopamine agonistsPhase 4, Phase 3632
38AnestheticsPhase 49596
39BB 1101Phase 4, Phase 1, Phase 22171
40Isophane Insulin, HumanPhase 4151
41Isophane insulin, beefPhase 4151
42Insulin, IsophanePhase 4252
43Dexamethasone 21-phosphatePhase 4, Phase 1, Phase 22171
44Dexamethasone acetatePhase 4, Phase 1, Phase 221711177-87-3
45Anticholesteremic AgentsPhase 42025
46Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 118340
47Dopamine AgentsPhase 4, Phase 3, Phase 23836
48Antiparkinson AgentsPhase 4, Phase 3, Phase 21574
49Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 41998
50
LactitolPhase 4336585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac

Interventional clinical trials:

(show top 50)    (show all 280)
idNameStatusNCT IDPhase
1Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) PatientsUnknown statusNCT01246310Phase 4
2Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In RemissionUnknown statusNCT01901666Phase 4
3Glargine Versus NPH in Patients With Chronic Kidney DiseaseCompletedNCT02451917Phase 4
4Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term ResultsCompletedNCT00858104Phase 4
5Cardiac Valve Complications in Prolactinomas Treated With CabergolineCompletedNCT00460616Phase 4
6Body Composition, Glucose Metabolism, Insulin Resistance and Gene Expression in Muscle Cells in Healthy Overweight WomenCompletedNCT00145392Phase 4
7Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled StudyCompletedNCT01021579Phase 4
8Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.RecruitingNCT01953107Phase 4
9Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyRecruitingNCT02060383Phase 4
10Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.RecruitingNCT01794793Phase 4
11A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsActive, not recruitingNCT01525550Phase 4
12Reflexology's Effect on Polycystic Ovary Syndrome (PCOS)Unknown statusNCT00744510Phase 3
13Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot StudyUnknown statusNCT00746148Phase 3
14Diabetes Prevention Program Outcomes StudyUnknown statusNCT00038727Phase 3
15Cinacalcet to Treat Familial Primary HyperparathyroidismCompletedNCT00325104Phase 3
16Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine TumoursCompletedNCT00353496Phase 3
17The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes MellitusCompletedNCT00700817Phase 3
18Comparison of Two Needles (ProCore vs EchoTip) for the Diagnosis of Pancreatic Solid Mass Under EUSCompletedNCT01479803Phase 3
19Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic CancerCompletedNCT01360853Phase 3
20Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late RelapseCompletedNCT00189553Phase 3
21An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.CompletedNCT01582061Phase 3
22A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related DiseasesCompletedNCT02153398Phase 3
23Study of Paclitaxel in Patients With Ovarian CancerCompletedNCT00989131Phase 3
24PGL4001 Versus Placebo in Uterine MyomasCompletedNCT00755755Phase 3
25Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity CancerCompletedNCT00483782Phase 3
26A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic CancerRecruitingNCT02395016Phase 3
27Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerRecruitingNCT02947685Phase 3
28A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast CancerRecruitingNCT03168880Phase 3
29A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT02993731Phase 3
30Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With ChemotherapyRecruitingNCT02404363Phase 3
31Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)RecruitingNCT02718417Phase 3
32Efficacy and Safety Evaluation of Osilodrostat in Cushing's DiseaseRecruitingNCT02697734Phase 3
33Dopamine Agonist Treatment of Non-functioning Pituitary AdenomasRecruitingNCT02288962Phase 3
34Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's DiseaseRecruitingNCT02180217Phase 3
35Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative ResectionRecruitingNCT02506842Phase 3
36Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.Active, not recruitingNCT02422615Phase 3
37An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid CancerActive, not recruitingNCT00410761Phase 3
38Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid CancerActive, not recruitingNCT00704730Phase 3
39Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO TreatmentNot yet recruitingNCT02705651Phase 3
40[68 Ga]-DOTANOC PET/CT in GEP-NETsNot yet recruitingNCT02608203Phase 2, Phase 3
41Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian CancerNot yet recruitingNCT03180177Phase 3
42GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 DiabetesTerminatedNCT00300105Phase 3
43GALLANT 9 Tesaglitazar vs. Placebo in Combination With InsulinTerminatedNCT00242372Phase 3
44GALLANT 5 Tesaglitazar Versus MetforminTerminatedNCT00214591Phase 3
45GALLANT 2 Tesaglitazar vs. PlaceboTerminatedNCT00252772Phase 3
46GALLANT 8 Tesaglitazar Add-on to MetforminTerminatedNCT00251953Phase 3
47GALLANT 22 Tesaglitazar vs. PlaceboTerminatedNCT00252837Phase 3
48GALLANT 4 Tesaglitazar vs. GlibenclamideTerminatedNCT00255541Phase 3
49GALLANT 7 Tesaglitazar Add-on to SulphonylureaTerminatedNCT00251940Phase 3
50Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell TransplantTerminatedNCT00324324Phase 3

Search NIH Clinical Center for Multiple Endocrine Neoplasia Iia


Cochrane evidence based reviews: multiple endocrine neoplasia type 2a

Genetic Tests for Multiple Endocrine Neoplasia Iia

About this section

Genetic tests related to Multiple Endocrine Neoplasia Iia:

id Genetic test Affiliating Genes
1 Multiple Endocrine Neoplasia, Type 227
2 Multiple Endocrine Neoplasia, Type 2a27
3 Multiple Endocrine Neoplasia Iia27
4 Multiple Endocrine Neoplasia Type 224 RET
5 Multiple Endocrine Neoplasia Type 2a24

Anatomical Context for Multiple Endocrine Neoplasia Iia

About this section

MalaCards organs/tissues related to Multiple Endocrine Neoplasia Iia:

36
Thyroid, Tongue, Colon, Skin, Bone, Adrenal gland

Publications for Multiple Endocrine Neoplasia Iia

About this section

Articles related to Multiple Endocrine Neoplasia Iia:

idTitleAuthorsYear
1
Atypical presentation of pheochromocytoma as part of multiple endocrine neoplasia IIa in pregnancy. (14607057)
2003
2
Total bilateral laparoscopic adrenalectomy in patients with Cushing's syndrome and multiple endocrine neoplasia (IIa). (9069136)
1997
3
Multiple endocrine neoplasia IIA found at autopsy. (2882037)
1987
4
Linkage and chromosome study of multiple endocrine neoplasia IIa. (6134579)
1983
5
Unilateral versus bilateral adrenalectomy in multiple endocrine neoplasia IIA. (6135282)
1983
6
Medullary carcinoma of the thyroid in the multiple endocrine neoplasia IIA syndrome. (7282994)
1981

Variations for Multiple Endocrine Neoplasia Iia

About this section

UniProtKB/Swiss-Prot genetic disease variations for Multiple Endocrine Neoplasia Iia:

70 (show all 28)
id Symbol AA change Variation ID SNP ID
1RETp.Cys609TyrVAR_006306rs77939446
2RETp.Cys611TrpVAR_006308rs80069458
3RETp.Cys611TyrVAR_006309rs377767397
4RETp.Cys618GlyVAR_006310rs76262710
5RETp.Cys618ArgVAR_006311rs76262710
6RETp.Cys618PheVAR_006312rs79781594
7RETp.Cys618SerVAR_006313rs79781594
8RETp.Cys618TyrVAR_006314rs79781594
9RETp.Cys620GlyVAR_006315rs77316810
10RETp.Cys620ArgVAR_006316rs77316810
11RETp.Cys620SerVAR_006317rs77503355
12RETp.Cys620PheVAR_006318rs77503355
13RETp.Cys620TyrVAR_006319rs77503355
14RETp.Cys630PheVAR_006320rs377767405
15RETp.Cys634GlyVAR_006323rs75076352
16RETp.Cys634PheVAR_006324rs75996173
17RETp.Cys634TyrVAR_006325rs75996173
18RETp.Cys634ArgVAR_006326rs75076352
19RETp.Cys634SerVAR_006327rs75076352
20RETp.Cys634TrpVAR_006328rs77709286
21RETp.Cys609GlyVAR_009470rs77558292
22RETp.Cys609ArgVAR_009471rs77558292
23RETp.Cys611ArgVAR_009473rs377767391
24RETp.Cys611SerVAR_009474rs377767391
25RETp.Cys620TrpVAR_009475rs79890926
26RETp.Ala640GlyVAR_009480rs78935588
27RETp.Leu790PheVAR_009482rs75030001
28RETp.Tyr791PheVAR_009483rs77724903

Clinvar genetic disease variations for Multiple Endocrine Neoplasia Iia:

5 (show all 36)
id Gene Variation Type Significance SNP ID Assembly Location
1RETNM_ 020630.4(RET): c.1852T> G (p.Cys618Gly)SNVPathogenicrs76262710GRCh37Chr 10, 43609096: 43609096
2RETNM_ 020975.4(RET): c.1900T> G (p.Cys634Gly)SNVPathogenicrs75076352GRCh37Chr 10, 43609948: 43609948
3RETNM_ 020975.4(RET): c.1901G> A (p.Cys634Tyr)SNVPathogenic/ Likely pathogenicrs75996173GRCh37Chr 10, 43609949: 43609949
4RETNM_ 020630.4(RET): c.1901G> C (p.Cys634Ser)SNVPathogenicrs75996173GRCh37Chr 10, 43609949: 43609949
5RETNM_ 020630.4(RET): c.1901G> T (p.Cys634Phe)SNVPathogenicrs75996173GRCh37Chr 10, 43609949: 43609949
6RETNM_ 020630.4(RET): c.1833C> G (p.Cys611Trp)SNVPathogenicrs80069458GRCh37Chr 10, 43609077: 43609077
7RETNM_ 020975.4(RET): c.1853G> C (p.Cys618Ser)SNVPathogenicrs79781594GRCh37Chr 10, 43609097: 43609097
8RETNM_ 020630.4(RET): c.1858T> C (p.Cys620Arg)SNVPathogenicrs77316810GRCh37Chr 10, 43609102: 43609102
9RETNM_ 020630.4(RET): c.1859G> A (p.Cys620Tyr)SNVPathogenic/ Likely pathogenicrs77503355GRCh37Chr 10, 43609103: 43609103
10RETNM_ 020975.4(RET): c.1900T> C (p.Cys634Arg)SNVPathogenic/ Likely pathogenicrs75076352GRCh37Chr 10, 43609948: 43609948
11RETNM_ 020630.4(RET): c.1902C> G (p.Cys634Trp)SNVPathogenic/ Likely pathogenicrs77709286GRCh37Chr 10, 43609950: 43609950
12RETNM_ 020975.4(RET): c.2753T> C (p.Met918Thr)SNVPathogenic/ Likely pathogenicrs74799832GRCh37Chr 10, 43617416: 43617416
13RETNM_ 020630.4(RET): c.1859G> T (p.Cys620Phe)SNVPathogenicrs77503355GRCh37Chr 10, 43609103: 43609103
14RETNM_ 020630.4(RET): c.1852T> C (p.Cys618Arg)SNVPathogenic/ Likely pathogenicrs76262710GRCh37Chr 10, 43609096: 43609096
15RETNM_ 020630.4(RET): c.2304G> C (p.Glu768Asp)SNVPathogenic/ Likely pathogenicrs78014899GRCh37Chr 10, 43613840: 43613840
16RETNM_ 020975.4(RET): c.1826G> A (p.Cys609Tyr)SNVPathogenic/ Likely pathogenicrs77939446GRCh37Chr 10, 43609070: 43609070
17RETNM_ 020975.4(RET): c.2370G> C (p.Leu790Phe)SNVPathogenicrs75030001GRCh37Chr 10, 43613906: 43613906
18RETNM_ 020975.4(RET): c.1941C> T (p.Ile647=)SNVrisk factorrs75225191GRCh37Chr 10, 43609989: 43609989
19RETNM_ 020630.4(RET): c.1597G> T (p.Gly533Cys)SNVPathogenicrs75873440GRCh37Chr 10, 43607621: 43607621
20RETNM_ 020975.4(RET): c.2671T> G (p.Ser891Ala)SNVPathogenic/ Likely pathogenicrs75234356GRCh37Chr 10, 43615592: 43615592
21RETNM_ 020630.4(RET): c.2586_ 2592delGCAGTAT (p.Met862Ilefs)deletionPathogenicrs794727130GRCh37Chr 10, 43615172: 43615178
22RETNM_ 020630.4(RET): c.1825T> G (p.Cys609Gly)SNVPathogenicrs77558292GRCh37Chr 10, 43609069: 43609069
23RETNM_ 020975.4(RET): c.1853G> A (p.Cys618Tyr)SNVPathogenic/ Likely pathogenicrs79781594GRCh37Chr 10, 43609097: 43609097
24RETNM_ 020630.4(RET): c.1888T> C (p.Cys630Arg)SNVPathogenic/ Likely pathogenicrs377767404GRCh37Chr 10, 43609936: 43609936
25RETNM_ 020630.4(RET): c.1891_ 1893delGAC (p.Asp631del)deletionPathogenicrs377767435GRCh37Chr 10, 43609939: 43609941
26RETNM_ 020630.4(RET): c.1891G> T (p.Asp631Tyr)SNVPathogenicrs377767406GRCh37Chr 10, 43609939: 43609939
27RETNM_ 020630.4(RET): c.1892_ 1903dupACGAGCTGTGCC (p.Cys634_ Arg635insHisGluLeuCys)duplicationPathogenicrs377767436GRCh37Chr 10, 43609940: 43609951
28RETNM_ 020630.4(RET): c.1900_ 1908dupTGCCGCACG (p.Thr636_ Val637insCysArgThr)duplicationPathogenicrs377767437GRCh37Chr 10, 43609948: 43609956
29RETNM_ 020630.4(RET): c.2080C> T (p.Arg694Trp)SNVLikely pathogenicrs193922700GRCh37Chr 10, 43610128: 43610128
30RETNM_ 020975.4(RET): c.2410G> A (p.Val804Met)SNVPathogenicrs79658334GRCh37Chr 10, 43614996: 43614996
31RETNM_ 020630.4(RET): c.1826G> C (p.Cys609Ser)SNVPathogenicrs77939446GRCh37Chr 10, 43609070: 43609070
32RETNM_ 020630.4(RET): c.2304G> T (p.Glu768Asp)SNVPathogenic/ Likely pathogenicrs78014899GRCh37Chr 10, 43613840: 43613840
33RETNM_ 020630.4(RET): c.2410G> C (p.Val804Leu)SNVPathogenic/ Likely pathogenicrs79658334GRCh37Chr 10, 43614996: 43614996
34RETNM_ 020975.4(RET): c.1901_ 1902delGCinsTG (p.Cys634Leu)indelPathogenicrs377767409GRCh37Chr 10, 43609949: 43609950
35RETNM_ 020975.4(RET): c.2647_ 2648delGCinsTT (p.Ala883Phe)indelPathogenic/ Likely pathogenicrs377767429GRCh37Chr 10, 43615568: 43615569
36RETNM_ 020975.4(RET): c.2689C> T (p.Arg897Ter)SNVPathogenicrs1060500759GRCh38Chr 10, 43120162: 43120162

Cosmic variations for Multiple Endocrine Neoplasia Iia:

8 (show top 50)    (show all 59)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM965RETthyroid,NS,carcinoma,medullary carcinomac.2753T>Cp.M918T11
2COSM29806RETthyroid,NS,carcinoma,medullary carcinomac.1888T>Gp.C630G11
3COSM29805RETthyroid,NS,carcinoma,medullary carcinomac.1859G>Cp.C620S11
4COSM552KRASthyroid,NS,carcinoma,medullary carcinomac.182A>Gp.Q61R11
5COSM476BRAFthyroid,NS,carcinoma,medullary carcinomac.1799T>Ap.V600E11
6COSM966RETthyroid,NS,carcinoma,medullary carcinomac.1900T>Cp.C634R11
7COSM499HRASthyroid,NS,carcinoma,medullary carcinomac.182A>Gp.Q61R11
8COSM29803RETthyroid,NS,carcinoma,medullary carcinomac.1852T>Cp.C618R11
9COSM584NRASthyroid,NS,carcinoma,medullary carcinomac.182A>Gp.Q61R11
10COSM486HRASthyroid,NS,carcinoma,medullary carcinomac.37G>Cp.G13R11
11COSM520KRASthyroid,NS,carcinoma,medullary carcinomac.35G>Tp.G12V11
12COSM3437784RETthyroid,NS,carcinoma,medullary carcinomac.2206G>Ap.G736R11
13COSM1732634HRASthyroid,NS,carcinoma,medullary carcinomac.216G>Ap.M72I11
14COSM518KRASthyroid,NS,carcinoma,medullary carcinomac.34G>Cp.G12R11
15COSM974RETthyroid,NS,carcinoma,medullary carcinomac.1901G>Ap.C634Y11
16COSM498HRASthyroid,NS,carcinoma,medullary carcinomac.182A>Tp.Q61L11
17COSM549KRASthyroid,NS,carcinoma,medullary carcinomac.181C>Ap.Q61K11
18COSM19900KRASthyroid,NS,carcinoma,medullary carcinomac.437C>Tp.A146V11
19COSM133167RETthyroid,NS,carcinoma,medullary carcinomac.2647G>Tp.A883S11
20COSM517KRASthyroid,NS,carcinoma,medullary carcinomac.34G>Ap.G12S11
21COSM975RETthyroid,NS,carcinoma,medullary carcinomac.1902C>Gp.C634W11
22COSM4170226RETthyroid,NS,carcinoma,medullary carcinomac.1946C>Tp.S649L11
23COSM496HRASthyroid,NS,carcinoma,medullary carcinomac.181C>Ap.Q61K11
24COSM21338RETthyroid,NS,carcinoma,medullary carcinomac.2304G>Cp.E768D11
25COSM553KRASthyroid,NS,carcinoma,medullary carcinomac.182A>Tp.Q61L11
26COSM482HRASthyroid,NS,carcinoma,medullary carcinomac.34G>Cp.G12R11
27COSM963RETthyroid,NS,carcinoma,medullary carcinomac.2701G>Ap.E901K11
28COSM249792RETthyroid,NS,carcinoma,medullary carcinomac.2041C>Tp.Q681*11
29COSM5598719RETthyroid,NS,carcinoma,medullary carcinomac.2137G>Ap.E713K11
30COSM960RETthyroid,NS,carcinoma,medullary carcinomac.2650G>Ap.E884K11
31COSM14320VHLthyroid,NS,carcinoma,medullary carcinomac.233A>Tp.N78I11
32COSM959RETthyroid,NS,carcinoma,medullary carcinomac.2627C>Tp.A876V11
33COSM961RETthyroid,NS,carcinoma,medullary carcinomac.2723G>Ap.R908K11
34COSM20889RETthyroid,NS,carcinoma,medullary carcinomac.2761G>Ap.E921K11
35COSM964RETthyroid,NS,carcinoma,medullary carcinomac.1888T>Cp.C630R11
36COSM583NRASthyroid,NS,carcinoma,medullary carcinomac.182A>Tp.Q61L11
37COSM528KRASthyroid,NS,carcinoma,medullary carcinomac.37G>Ap.G13S11
38COSM27159KRASthyroid,NS,carcinoma,medullary carcinomac.187G>Ap.E63K11
39COSM29804RETthyroid,NS,carcinoma,medullary carcinomac.1858T>Cp.C620R11
40COSM489HRASthyroid,NS,carcinoma,medullary carcinomac.38G>Tp.G13V11
41COSM1237679MDC1thyroid,NS,carcinoma,medullary carcinomac.6266C>Ap.T2089N11
42COSM304967HRASthyroid,NS,carcinoma,medullary carcinomac.351G>Tp.K117N11
43COSM971RETthyroid,NS,carcinoma,medullary carcinomac.2296C>Tp.P766S11
44COSM249789RETthyroid,NS,carcinoma,medullary carcinomac.2117T>Cp.V706A11
45COSM481HRASthyroid,NS,carcinoma,medullary carcinomac.34G>Tp.G12C11
46COSM1247975CDKN2Cthyroid,NS,carcinoma,medullary carcinomac.214G>Ap.A72T11
47COSM980RETthyroid,NS,carcinoma,medullary carcinomac.1853G>Ap.C618Y11
48COSM958RETthyroid,NS,carcinoma,medullary carcinomac.2242G>Tp.G748C11
49COSM918118RETthyroid,NS,carcinoma,medullary carcinomac.2038G>Ap.A680T11
50COSM4445256CDKN2Cthyroid,NS,carcinoma,medullary carcinomac.235A>Gp.R79G11

Expression for genes affiliated with Multiple Endocrine Neoplasia Iia

About this section
Search GEO for disease gene expression data for Multiple Endocrine Neoplasia Iia.

Pathways for genes affiliated with Multiple Endocrine Neoplasia Iia

About this section

GO Terms for genes affiliated with Multiple Endocrine Neoplasia Iia

About this section

Cellular components related to Multiple Endocrine Neoplasia Iia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone)GO:00057499.5SDHB, SDHD

Biological processes related to Multiple Endocrine Neoplasia Iia according to GeneCards Suite gene sharing:

(show all 20)
idNameGO IDScoreTop Affiliating Genes
1enteric nervous system developmentGO:004848410.6GDNF, RET
2neural crest cell migrationGO:000175510.5GDNF, RET
3beta-catenin-TCF complex assemblyGO:190483710.5CDC73, MEN1
4response to painGO:004826510.4CALCA, RET
5adenylate cyclase-activating G-protein coupled receptor signaling pathwayGO:000718910.3CALCA, PTH
6positive regulation of cAMP biosynthetic processGO:003081910.2CALCA, PTH
7axon guidanceGO:000741110.2GDNF, GFRA1, RET
8positive regulation of ossificationGO:004577810.2CALCA, PTH
9positive regulation of extrinsic apoptotic signaling pathway in absence of ligandGO:200124110.1NF1, RET
10negative regulation of osteoclast differentiationGO:004567110.1CALCA, NF1
11positive regulation of adenylate cyclase activityGO:004576210.1CALCA, NF1
12metanephros developmentGO:000165610.0GDNF, NF1
13peripheral nervous system developmentGO:000742210.0GDNF, NF1
14negative regulation of fibroblast proliferationGO:00481479.9CDC73, NF1
15tricarboxylic acid cycleGO:00060999.9SDHB, SDHD
16ureteric bud developmentGO:00016579.8GDNF, RET
17sympathetic nervous system developmentGO:00484859.8GDNF, NF1
18positive regulation of GTPase activityGO:00435479.3GDNF, GFRA1, NF1, RET
19regulation of gene expressionGO:00104689.2GDNF, NF1, PTH
20MAPK cascadeGO:00001659.0GDNF, GFRA1, MEN1, NF1, RET

Molecular functions related to Multiple Endocrine Neoplasia Iia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1Ras guanyl-nucleotide exchange factor activityGO:00050889.7GDNF, GFRA1, RET
2succinate dehydrogenase (ubiquinone) activityGO:00081779.6SDHB, SDHD
3ubiquinone bindingGO:00480399.5SDHB, SDHD

Sources for Multiple Endocrine Neoplasia Iia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet